Researchers have identified a potential drug candidate that may reverse the progression of a challenging form of heart failure, according to findings from a study conducted at the University of Arizona College of Medicine – Tucson’s Sarver Heart Center. The study, which utilized mouse models, highlights promising developments in addressing heart conditions that currently have limited treatment options. The research findings were published in the scientific journal *Cell Metabolism*.
The investigation was led by a physician-scientist affiliated with the Sarver Heart Center and focused on exploring therapeutic approaches for heart failure with preserved ejection fraction (HFpEF), a condition known for its complexity and resistance to conventional treatments. Using preclinical models, researchers observed that the drug candidate demonstrated an ability to reverse disease progression associated with HFpEF. While further studies are required to determine its efficacy and safety in humans, this discovery could pave the way for expanded treatment possibilities for patients suffering from this difficult-to-treat cardiac condition…